Anti-hepatitis C antibodies and antigen binding fragments thereof
AssigneeUnited Kingdom Research and Innovation
InventorsArvind Patel, Ania Owsianka
Life of this patent
Estimating the term…
Abstract
The invention provides an antibody or antigen binding fragment thereof capable of binding to the antigen binding pocket of the AP33 antibody, wherein said antibody or antigen binding fragment thereof comprises VL CDR1 (L1), VL CDR2 (L2), and VL CDR3 (L3) consisting of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively, and comprises VH CDR1 (H1), VH CDR2 (H2), and VH CDR3 (H3) consisting of the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 respectively. The invention also provides compositions, methods, nucleic acids and uses.
Claims19
An anti-idiotypic antibody or antigen binding fragment thereof said anti-idiotypic antibody or antigen binding fragment thereof comprising VL CDR1 (L1), VL CDR2 (L2), and VL CDR3 (L3) consisting of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively, and VH CDR1 (H1), VH CDR2 (H2), and VH CDR3 (H3) consisting of the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 respectively, wherein said anti-idiotypic antibody or antigen binding fragment thereof specifically binds to an antigen binding pocket of an AP33 antibody.
A nucleic acid comprising a nucleotide sequence encoding a variable heavy chain domain, a variable light chain domain, or both the variable heavy chain domain and the variable light chain domain of an anti-idiotypic antibody or antigen binding fragment according, or a complement thereof, wherein the variable light chain domain comprises VL CDR1 (L1), VL CDR2 (L2), and VL CDR3 (L3), consisting of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively, and the variable heavy chain domain comprises VH CDR1 (H1), VH CDR2 (H2), and VH CDR3 (H3), consisting of the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 respectively.
A composition comprising an anti-idiotypic antibody or antigen binding fragment thereof and a pharmaceutically acceptable carrier or excipient and optionally one or both of a carrier protein and an adjuvant, wherein said anti-idiotypic antibody or antigen binding fragment thereof comprises VL CDR1 (L1), VL CDR2 (L2), and VL CDR3 (L3), consisting of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively, and VH CDR1 (H1), VH CDR2 (H2), and VH CDR3 (H3), consisting of the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 respectively, and said anti-idiotypic antibody or antigen binding fragment thereof specifically binds to an antigen binding pocket of an AP33 antibody.
Dependencies are inferred from the claim text.